NEW YORK (GenomeWeb) – Researchers from two pharmaceutical companies are pursuing drugs that target the ANGPTL3 gene in a bid to treat heart disease.

The companies hope to recapitulate, to some degree, the lower triglyceride and cholesterol levels seen among people with naturally occurring loss-of-function mutations in ANGPTL3. People who are homozygous for such mutations have some 70 percent lower plasma triglycerides and LDL cholesterol levels than those without.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.